Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
HCV Advocate

Tuesday, November 8, 2011

SCYNEXIS Presents Data Demonstrating that SCY-635 Restores the Body's Innate Immune Response to HCV and Could be an Effective Replacement for Recombinant Interferon

--Major progress towards an all oral treatment strategy-- 

RESEARCH TRIANGLE PARK, N.C., Nov 07, 2011 (BUSINESS WIRE) -- Drug discovery company SCYNEXIS, Inc. today presented data demonstrating that SCY-635--a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection--reactivates the body's natural defense mechanism, making it capable of inhibiting replication of the virus. The data positions SCY-635 as a potential replacement for recombinant interferon--a component of the standard of care for hepatitis C treatment that is associated with significant side effects. The data were presented in a poster session at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco. SCY-635 is currently undergoing Phase 2 studies. 

"The results of this study introduce a completely novel mechanism to treat HCV and suggest that our oral cyclophilin inhibitor, SCY-635, could potentially replace recombinant interferon--a primary goal in the development of new treatment protocols for this disease," said Yves Ribeill, Ph.D., President and Chief Executive Officer of SCYNEXIS. "HCV is a complex disease where the virus cloaks and hides itself from the body's immune system. SCY-635 uncloaks the virus -- making it visible to the immune system. In studies conducted to date, SCY-635 has been well-tolerated and demonstrated single-agent, clinically meaningful activity. It has also demonstrated an excellent in vitro drug - drug interaction profile with other approved products and leading products in clinical development, suggesting that SCY-635 could play an important role in the quest for a new standard of care in HCV."



No comments:

Post a Comment